Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

40.0%

4 terminated/withdrawn out of 10 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A

6(75.0%)

Phase 2

1(12.5%)

Phase 1

1(12.5%)

8Total

N/A(6)

Phase 2(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT06778447Not ApplicableRecruiting

Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft in Participants With Degenerative Disc Disease

Role: lead

NCT06345690Recruiting

VIA Disc NP Registry 3.0

Role: lead

NCT06615505Phase 2Recruiting

ASCEND: A Clinical Trial to Evaluate the Safety and Effectiveness of VIA Disc NP, a Supplement for Degenerated Intervertebral Discs

Role: lead

NCT04652687Terminated

VIA Disc NP Registry

Role: lead

NCT05412277Not ApplicableActive Not Recruiting

VIA Disc Nucleus Pulposus Older Patients Pilot

Role: lead

NCT05201287Not ApplicableActive Not Recruiting

VIA Disc NP Pilot for Patients With Symptomatic Degenerated Discs

Role: lead

NCT05196191Not ApplicableTerminated

Wound Healing Following Penile Prosthesis Implant

Role: lead

NCT04835389Phase 1Withdrawn

Study of AlloGen® Liquid Intra-articular Injection for Knee Osteoarthritis

Role: lead

NCT03709901Not ApplicableUnknown

Viable Allograft Supplemented Disc Regeneration in the Treatment of Patients With Low Back Pain

Role: lead

NCT02932020Not ApplicableWithdrawn

AlloGen-LI Treatment of Spinal Stenosis

Role: collaborator

All 10 trials loaded